Short answer
Cogent Biosciences, Inc. (COGT) filed an 8-K current report with the SEC on September 2, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement). Five-year supply agreement with Hovione for bezuclastinib spray-dried dispersion and tablets.
Cogent Biosciences, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Five-year supply agreement with Hovione for bezuclastinib spray-dried dispersion and tablets
- Minimum purchase percentages decline over the contract term, creating initial supplier concentration and volume commitments
- Quarterly rolling forecasts, with near-term quantities binding and longer-term estimates subject to adjustment limits
- Automatic two-year renewals, with termination rights for breach, force majeure, insolvency, and regulatory or legal developments
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Cogent Biosciences, Inc. 8-K filings
Get the next COGT 8-K as it lands
Follow COGT for push alerts, or ask the research agent what this filing means.